Reproxalap is under clinical development by Aldeyra Therapeutics and currently in the Phase III and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Reproxalap’s likelihood of approval (LoA) and phase transition for Allergic Conjunctivitis took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Reproxalap Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Reproxalap overview

Reproxalap (ADX-102) is under development for allergic conjunctivitis, dry eye syndrome and coronavirus disease 2019 (COVID-19). It is administered through oral, dermal and ophthalmic routes. It is developed based on pro-inflammatory reactive aldehyde species (RASP) scavenger platform. It is also under development for oral formulation indications including amino acid metabolism disorder including succinic semialdehyde dehydrogenase deficiency (SSADH) (oral formulation).

The drug candidate was also under development for the treatment of sjogren-larsson syndrome, discoid lupus erythematosus, congenital ichthyosis in subjects with dermatitis including contact dermatitis and allergic dermatitis, ocular inflammation including ocular rosacea with meibomian gland dysfunction, radiation-induced oral mucositis and acute non-infectious anterior uveitis.

Aldeyra Therapeutics overview

Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.

Quick View Reproxalap LOA Data

Report Segments
  • Innovator
Drug Name
  • Reproxalap
Administration Pathway
  • Ophthalmic
  • Oral
  • Topical
Therapeutic Areas
  • Dermatology
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Ophthalmology
  • Toxicology
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.